Longbow offers two healthcare enterprise investment schemes which target growth areas within the life sciences, health and well-being sectors.
The approved EIS fund has a defined investment period of one year and a portfolio of 8-10 UK-based unquoted stocks, designed for investors with an income tax liability in the current tax year. The arrowhead EIS fund invests in 10-15 companies over a period of 18-24 months and is intended for investors with anticipated tax liabilities in the next two years.
Longbow partner Julian Hickman says the forward-looking funds offer a convincing growth story for investors in the current downturn. He says: “Healthcare is a broad market which covers many different technologies, markets and products so it offers a good basis for diversification. The challenge in early stage venture capital is to be able to develop the technology and market it effectively – this doesn’t change dramatically in a good or bad market.”